Success Metrics

Clinical Success Rate
61.9%

Based on 13 completed trials

Completion Rate
62%(13/21)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
8(35%)

Phase Distribution

Ph not_applicable
2
9%
Ph phase_3
13
57%
Ph phase_2
3
13%
Ph phase_4
4
17%

Phase Distribution

0

Early Stage

3

Mid Stage

17

Late Stage

Phase Distribution22 total trials
Phase 2Efficacy & side effects
3(13.6%)
Phase 3Large-scale testing
13(59.1%)
Phase 4Post-market surveillance
4(18.2%)
N/ANon-phased studies
2(9.1%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

61.9%

13 of 21 finished

Non-Completion Rate

38.1%

8 ended early

Currently Active

0

trials recruiting

Total Trials

23

all time

Status Distribution
Completed(13)
Terminated(8)
Other(2)

Detailed Status

Completed13
Terminated8
unknown2

Development Timeline

Analytics

Development Status

Total Trials
23
Active
0
Success Rate
61.9%
Most Advanced
Phase 4

Trials by Phase

Phase 23 (13.6%)
Phase 313 (59.1%)
Phase 44 (18.2%)
N/A2 (9.1%)

Trials by Status

terminated835%
completed1357%
unknown29%

Recent Activity

Clinical Trials (23)

Showing 20 of 23 trialsScroll for more
NCT00232089Phase 3

Assessment of Efficacy and Safety of Tegaserod Treatment and Placebo in Women With Dyspepsia

Completed
NCT00348634Phase 4

Effect of Tegaserod on Orocecal Transit in Elderly Chronic Constipation Patients

Terminated
NCT00390975Phase 4

Effect of Tegaserod on Gastric Emptying in Patients With Diabetic Gastroparesis

Terminated
NCT00399659Phase 3

Safety and Efficacy of Tegaserod in Opioid-induced Constipation in Patients With Non-cancer Pain.

Terminated
NCT00414024Phase 3

Safety and Efficacy of Tegaserod in Opioid-induced Constipation in Patients With Non-cancer Pain.

Terminated
NCT00365820Phase 2

Efficacy and Safety of Tegaserod in Opioid-induced Constipation in Patients With Non-cancer Pain

Terminated
NCT00171431Phase 3

The Effect of Tegaserod on Patterns of Flow in the Small Bowel of Patients With Irritable Bowel Syndrome (IBS)

Terminated
NCT00142974Phase 2

Assessment of the Effect of Tegaserod (2 mg Tid and 6 mg Tid) on Dyspeptic Symptoms in Diabetic Patients With Symptoms of Diabetic Gastropathy

Terminated
NCT00563758Not Applicable

A Randomized, Double-blind, Placebo-controlled Multicenter Study to Assess the Efficacy, Safety and Tolerability of Tegaserod 2 mg Bid vs Placebo in Patients With Chronic Constipation

Terminated
NCT00511771

A Treatment Investigational New Drug (tIND) Program of Tegaserod in Women With Irritable Bowel Syndrome With Constipation or With Chronic Idiopathic Constipation

Unknown
NCT00149851Phase 2

A Study to Assess the Efficacy, Safety and Tolerability of Tegaserod Alone and in Combination With Omeprazole Given Orally in Patients With Symptoms of Symptomatic Gastroesophageal Reflux Disease (sGERD)

Completed
NCT00563615Not Applicable

Study of Effect of Tegaserod on Small and Large Bowel Transit by Scintigraphic Method

Unknown
NCT00232024Phase 3

Assessment of Efficacy and Safety of Tegaserod Treatment and Placebo in Women With Dyspepsia

Completed
NCT00149877Phase 4

Efficacy, Safety and Tolerability of Tegaserod in Patients With Chronic Constipation

Completed
NCT00141089Phase 3

Assessment of Efficacy and Safety of Tegaserod in Male Patients With Chronic Constipation.

Completed
NCT00232102Phase 3

Extension Study to Assess the Long-Term Safety of Tegaserod in Women With Symptoms of Dyspepsia

Completed
NCT00232037Phase 3

Extension Study to Assess the Long-Term Safety of Tegaserod in Women With Symptoms of Dyspepsia

Completed
NCT00139568Phase 3

An Evaluation of the Efficacy and Safety of Tegaserod 6 mg Bid Given Orally to Chinese Patients With Chronic Constipation

Completed
NCT00171470Phase 3

The Role of Tegaserod Therapy in the Management of Dyspeptic Symptoms in Female Patients on Proton Pump Inhibitors for the Treatment of Heartburn.

Completed
NCT00171483Phase 3

Assessment of the Role of Tegaserod Therapy in the Management of Gastroesophageal Reflux Disease (GERD) Symptoms in Patients With Incomplete Response to Proton Pump Inhibitors (PPIs).

Completed

Drug Details

Intervention Type
DRUG
Total Trials
23